Top Tweets for #Veritac2
A few studies that we touched on during our #ESMOBreast26 highlights ๐ฃ๏ธ w/ @ErikaHamilton9 (a good starting point just before we walk into #ASCO26)!
โ
#VERITAC2
โ
#PREcoopERA
โ
#PHERGain
โ
#SATEEN & #BRE354
โ
#TROPIONBreast02
#OncTwitter #bcsm #MedTwitter @myESMO
Conference Highlights from #ESMOBreast26 (including recent approval) with @ErikaHamilton9
โ
#VERITAC2
โ
#PREcoopERA
โ
#PHERGain
โ
#SATEEN & #BRE354
โ
#TROPIONBreast02
Full ๐ฃ๏ธ:
โญ๏ธ OncBrothers & @OncUpdates website
โญ๏ธโOncology Brothersโ podcast
#OncTwitter #bcsm
Conference Highlights from #ESMOBreast26 (including recent approval) with @ErikaHamilton9
โ
#VERITAC2
โ
#PREcoopERA
โ
#PHERGain
โ
#SATEEN & #BRE354
โ
#TROPIONBreast02
Full ๐ฃ๏ธ:
โญ๏ธ OncBrothers & @OncUpdates website
โญ๏ธโOncology Brothersโ podcast
#OncTwitter #bcsm
#Vepdegestrant approved today by @US_FDA for the treatment for pts with #ESR1m #bcsm after PD on ET based on results from #VERITAC2.
Another options for our pts in the pre-tx setting, very excited about the safety profile with this agent!
@SarahCannonDocs
FDA Approval in #BreastCancer based on VERITAC-2
https://t.co/i5fUtCkdWt
On May 1, 2026, the FDA approved vepdegestrant, a heterobifunctional protein degrader, for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy. Approval was supported by the VERITAC-2 trial, where vepdegestrant improved progression-free survival versus fulvestrant (5.0 vs 2.1 months; HR 0.57) and increased response rates (19% vs 4%). Guardant360 CDx was simultaneously approved as a companion diagnostic to detect ESR1 mutations. Survival data remain immature at analysis.
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H
@nataliagandur @acampsmalea @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @Onco_Cifu88
Vepdegestrant (PROTAC ER degrader) @US_FDA โ
for HR+ metastatic breast based off #Veritac2 Ph III vs. (Fulvestrant) after CDK4/6i + AI:
- mPFS 5.0 vs 2.1 mos in ESR1m (HR=0.57)
- OS is immature
- Well-tolerated, low discontinuation
#bcsm @OncUpdates @OncoAlert
@marklewismd Btw....if we are throwing ourselves under the bus, take a look. While on stage after presenting #VERiTAC2 at #ASCO25, take a look at this gem my partner captured of me when " Vogel NY" asked a question. Ha- definitely pure joy ๐.
@marklewismd
The #OncoAlertTOPTweet๐จDay Two #ASCO25
Post from @matteolambe
First oral presentation at #ASCO25 and first
@NEJM
@ErikaHamilton9
presenting results of #VERITAC2 trial showing the first phase 3 efficacy data of #vepdegestrant in patients with #ESR1m advanced HR+/HER2- #BreastCancer
Post OncoAlert #OncoAlertAF
@nataliagandur
@acampsmalea
@BRicciutiMD
@yekeduz_emre
@HHorinouchi
@FadiHaddad_MD
@Abdallah81MD
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@bavilima
@realbowtiedoc
@Erman_Akkus
@Lucarecco
@GaiaGriguolo
@JankovicK
@matteolambe
@weoncologists
@E_de_Azambuja
@Icro_Meattini
First oral presentation at #ASCO25 and first @NEJM: super @ErikaHamilton9 presenting results of #VERITAC2 trial showing the first phase 3 efficacy data of #vepdegestrant in patients with #ESR1m advanced HR+/HER2- #BreastCancer
@OncoAlert @ASCO
1. #VERITAC2: Ph III,Vepdegestrant (PROTAC ER degrader) vs Fulvestrant after CDK4/6i + AI:
- mPFS 5.0 vs 2.1 mos in ESR1m (HR=0.57)
- No PFS benefit in all pts
- OS is immature
- Well-tolerated, low discontinuation
- New class of drug for ESR1m disease
2/8
Join us in Hall B1 this afternoon to hear the details.
What am I particularly excited about?
Of course 5.0 vs. 2.1 months for ESR1m
But...it's the tolerability! Discontinuations and reductions <5%!
#VERITAC2 #vepdegestrant #PROTAC #ASCO25 @SarahCannonDocs
Love @ASCO's patient summaries!
Patients are who we are here for. Communicating findings in lay person wording so everyone can learn is so important!
#VERITAC2 #PROTAC #bcsm #vepdegestrant #ASCO25
@SarahCannonDocs
Learn more from this #ASCO25 #VERITAC2 research summary for patients and families: Vepdegestrant shows promise in delaying time to cancer progression for ER+, HER2- advanced #BreastCancer with an ESR1 mutation: https://t.co/fkbn5gLixs
#BCSM
Learn more from this #ASCO25 #VERITAC2 research summary for patients and families: Vepdegestrant shows promise in delaying time to cancer progression for ER+, HER2- advanced #BreastCancer with an ESR1 mutation: https://t.co/fkbn5gLixs
#BCSM
๐จ #ASCO25
Vepdegestrant significantly improved PFS in patients with ESR1-mutant metastatic breast cancer!
๐ VERITAC-2:
โ Median PFS: 5.0 vs 2.1 months (HR: 0.57; p<0.001)
Promising results for next-gen SERDs!
#VERITAC2 #Vepdegestrant #mBC #ESR1 #OncoTwitter #BreastCancer
First oral presentation at #ASCO25 and first @NEJM: super @ErikaHamilton9 presenting results of #VERITAC2 trial showing the first phase 3 efficacy data of #vepdegestrant in patients with #ESR1m advanced HR+/HER2- #BreastCancer
@OncoAlert @ASCO
Join us in Hall B1 this afternoon to hear the details.
What am I particularly excited about?
Of course 5.0 vs. 2.1 months for ESR1m
But...it's the tolerability! Discontinuations and reductions <5%!
#VERITAC2 #vepdegestrant #PROTAC #ASCO25 @SarahCannonDocs
๐งฌ VERITAC-2 Trial (NEJM May 2025)
๐ Oral PROTAC ER degrader vepdegestrant vs. fulvestrant in ER+/HER2โ MBC post-CDK4/6i
๐ฏ Primary PFS Results: โ ESR1-mut+ โฌ๏ธ PFS:
โ5.0 vs 2.1 mo
โHR 0.58 | p < 0.001
โ ITT:
โ3.8 vs 3.6 mo
โHR 0.83 | NS (p = 0.07)
๐ ORR (ESR1-mut):
โ18.6% vs 4.0%
๐ All-oral, well tolerated. Low GI & QTc issues.
๐ BUT...
โ No benefit in unselected population
โ OS data immature
โ No chemo-pretreated patients
โ Cross-trial gains vs. elacestrant/imlunestrant need caution
โ Fulvestrant underperforms in ESR1-mut โ was that the bar?
๐ง Verdict: A cleaner, smarter SERD โ but biomarker-driven use essential.
#BreastCancer #ESR1 #ASCO25 #OncologyTrials #PROTAC #Vepdegestrant #MBC @ASCO @hoperugo @ErikaHamilton9 @stolaney1 @OncoAlert @brunolarvol
Topline results from Phase 3 VERITAC-2 clinical trial. The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to fulvestrant.
#LARVOL #VERITAC2 #Oncology #CancerResearch #CancerData #ClinicalTrials #OncologyDevelopments #BreastCancer | @Larvol | @stolaney1 | @SuyogCancer
Happy to get the word out about the ongoing #VERITAC2 trial with #vepdegestrant. We need better endocrine therapies post CDK4&6!
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER /HER2- advanced breast cancer https://t.co/U7j45dMv15
Last Seen Hashtags on Sotwe
forzahorizon5
Seen from United States
momson
Seen from United Kingdom
เธฃเธฑเธเธเธฒเธเธเธฒเธเธเธฐเธเธด
Seen from Thailand
painal #gayporn
Seen from Turkey
bnwo #pmv
Seen from Turkey
gayfurry
Seen from United States
TheChosen
Seen from United States
calvinklein
Seen from United States
ๆทซๆฏ
Seen from Korea
omegle () +video
Seen from South Africa
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.1M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.4M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.1M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.3M followers
KATY PERRY
@katyperry
88.7M followers
Taylor Swift
@taylorswift13
82.6M followers
Lady Gaga
@ladygaga
74.1M followers
Virat Kohli
@imvkohli
71.5M followers
Kim Kardashian
@kimkardashian
70.3M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.5M followers
Neymar Jr
@neymarjr
64.4M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.8M followers
X
@x
60.8M followers